drugset / Trial / NCT02017730
To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding in Lung Using PET (Positron Emission Tomography) In Healthy Volunteers
Non-randomizedParallel-groupOpen-labelBasic science
Summary
The purpose of this study is to assess the safety and tolerability of a novel positron emission tomography (PET) tracer \[11C\]BMT-136088 in healthy adult subjects for measurement of availability of Lysophosphatidic Acid (LPA1) receptors in the human lung and to use this tracer to assess LPA1 receptor occupancy using \[11C\]BMT-136088 in the human lung following oral administration of Bristol Myers Squibb (BMS)-986020.
Timeline
- Start
- 2014-01
- Primary completion
- 2015-01
- Completion
- 2015-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BMS-986020 | Small molecule | 50 mg | Oral |
| Subject | BMS-986020 | Small molecule | 150 mg | Oral |
| Subject | BMS-986020 | Small molecule | 300 mg | Oral |
| Subject | BMS-986020 | Small molecule | 600 mg | Oral |
| Subject | BMS-986020 | Small molecule | 1200 mg | Oral |
| Subject | BMS-986020 | Small molecule | 1500 mg | Oral |
| Subject | [11C]BMT-136088 | Diagnostic / imaging agent | — | Intravenous |
Indications
No indication recorded.